Squibb Company (NYSE:BMY) today announced that a randomized blinded
comparative Phase 3 study evaluating nivolumab versus dacarbazine (DTIC)
in patients with previously untreated BRAF wild-type advanced melanoma
was stopped early because an analysis conducted by the independent Data
Monitoring Committee (DMC) showed evidence of superior overall survival
in patients receiving nivolumab compared to the control arm.
for Phase 3 First-Line Melanoma Study of Nivolumab, an Investigational PD-1 Checkpoint Inhibitor, Demonstrates Superior Overall Survival Compared to Dacarbazine; Study Stopped Early investment picks